We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

PET Evaluation of Recurrent Differentiated Thyroid Cancer (THYROPET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01641679
Recruitment Status : Unknown
Verified June 2014 by The Netherlands Cancer Institute.
Recruitment status was:  Not yet recruiting
First Posted : July 17, 2012
Last Update Posted : June 17, 2014
Amsterdam UMC, location VUmc
UMC Utrecht
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Brief Summary:

After initial treatment of differentiated thyroid cancer patients (DTC) are followed by a blood test, a biomarker called thyroglobulin, in order to detect a possible recurrence. Nowadays patients are treated 'blindly' with high dose radioactive iodine to treat a suspected recurrence. However, the scan made after therapy to verify the effect of the treatment shows that in up to 50% the treatment could be considered as futile.

124I - a radioactive isotope - in combination with whole body PET became recently available for use in the follow-up of DTC. This could make it possible before the therapy with high dose radioactive iodine to determine the extensiveness of the disease and whether effect of the therapy could be expected. Additionally, recurrent DTC lesions that do not accumulate iodine can be found without the futile treatment with 131I. FDG-PET (another PET modality) is able to detect these lesions. The value of FDG-PET before 131I treatment however has not been tested.

The combination of these two diagnostic tools, 124I-PET and FDG-PET, has a potential to allow earlier and better restaging and selection for treatment

Condition or disease
Thyroid Neoplasms Differentiated Thyroid Cancer

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Recurrent Differentiated Thyroid Cancer: Towards Personalized Treatment Based on Evaluation of Tumor Characteristics With PET (THYROPET
Study Start Date : August 2012
Estimated Primary Completion Date : August 2015
Estimated Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Thyroid

Suspected recurrent DTC
100 patients with biochemically suspected recurrent DTC

Primary Outcome Measures :
  1. The number of futile high-dose 131I treatments that could have been avoided by implementation of pre-therapy imaging based on result of post-therapy scintigraphy [ Time Frame: Baseline and post-therapy ]
    In order to dertermine wheter a treatment could be considered futile a comparison between de I124-PET en post-therapy scan will be made and when the results are consistent we determine how many futile treatments could have been avoided when the I124 will be implemented in the future.

Secondary Outcome Measures :
  1. Synchronised QA/QC of 124I-PET in the Netherlands [ Time Frame: Before start study ]
    In order to make the scans quantifiable and comparable 124I-PET scans in this multicenter study a phantom study will be performed. The mean and median measured activity (Bq) in the different vials in the phantom will be assessed and compared to the known activity in the vial. In this way we will be able to create a calibration curve for each scanner.

  2. - Translational correlation of 124I-PET and FDG-PET with histopathology (where available) and treatment outcome, in an explorative setting. [ Time Frame: At follow-up ]
    - The outcome of the treatment is defined as a positive or negative post-therapy scan. This scan and both 124I-PET and FDG-PET will be correlated with histopathological features. The expression of different markers will be quantified in the samples. These results will also be compared with the results of the different scan modalities. In this way we aim to determine which histopathological features can predict outcome of the scans.

  3. - To investigate whether 124I-PET has the same diagnostic, dosimetric and prognostic yield during stimulation with rhTSH and hormone withdrawal combined with low-iodine diet. [ Time Frame: Baseline and during therapy ]
    Because 124I-PET will be performed both after stimulation with rhTSH and after withdrawal from levothyroxine it is possible to determine any differences in outcome from the two scan preparation strategies. Both visual assessment as the quantifiable data will be compared.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
100 patients with a history of DTC treated with total thyroidectomy and ablation who now have a suspicion of recurrence outside the neck based on a raised Tg and a negative neck ultrasound

Inclusion Criteria:

  • Patients with a history of differentiated thyroid cancer
  • After complete thyroidectomy and ablation of functional remnants with 131I.
  • Planned for blind high dose 131I treatment based on biochemically suspected recurrence, defined as a Tg-level above 2.0 ng/ml.
  • Ultrasonography of the neck performed < 2 months prior to inclusion.

Exclusion Criteria:

  • Age < 18 years
  • Pregnancy
  • Incapacitated subjects
  • Contrast enhanced CT performed < 4 months prior to inclusion
  • I-131 therapy performed < 12 months prior to inclusion
  • Indication for other therapy modality (ie. surgery in case of a positive ultrasonography, radiotherapy, embolization or chemotherapy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01641679

Layout table for location contacts
Contact: Jakob W Kist, MD +31641853004 j.kist@nki.nl
Contact: Marcel PM Stokkel, MD PhD +31205122283 m.stokkel@nki.nl

Layout table for location information
Rijnstate Hospital
Arnhem, Gelderland, Netherlands, 6815 AD
Contact: Vanessa JR Schelfhout, MD    +31 88 005 8888    VSchelfhout@rijnstate.nl   
Principal Investigator: Vanessa JR Schelfhout, MD PhD         
UMC St. Radboud Nijmegen
Nijmegen, Gelderland, Netherlands, 6525 GA
Contact: Martin Gotthardt, MD PhD    +31243611111    m.gotthardt@nucmed.umcn.nl   
Principal Investigator: Martin Gotthardt, MD PhD         
Sub-Investigator: Rick Hermsen, MD         
Bernard Verbeeten Institute
Tilburg, Noord-Braband, Netherlands, 5000 LA
Contact: Arjen B van Dijk, MD    +31 13 5947715    dijk.v.a@bvi.nl   
Principal Investigator: Arjen B van Dijk, MD         
Jeroen Bosch Hospital
Den Bosch, Noord-Brabant, Netherlands, 5223 GZ
Contact: Corneline J Hoekstra, MD PhD    +31 73 553 2690    C.Hoekstra@jbz.nl   
Principal Investigator: Corneline J Hoekstra, MD PhD         
Catharina Hospital
Eindhoven, Noord-Brabant, Netherlands, 5623 EJ
Contact: Dyde Huysmans, MD PhD    +31 40 239 9111    dyde.huysmans@catharinaziekenhuis.nl   
Principal Investigator: Dyde Huysmans, MD PhD         
Medical Center Alkmaar
Alkmaar, Noord-Holland, Netherlands, 1815JD
St. Lucas Andreas Hospital
Amsterdam, Noord-Holland, Netherlands, 1061 AE
Contact: Farida Sivro, MD    +31 20 510 8877    f.sivro@nki.nl   
Principal Investigator: Ferida Sivro, MD         
VUmc Medical Center
Amsterdam, Noord-Holland, Netherlands, 1081HV
Contact: Otto S Hoekstra, MD PhD    +31 20 4444214    os.hoekstra@vumc.nl   
Principal Investigator: Otto S Hoekstra, MD PhD         
Medical spectrum Twente
Enschede, Overijssel, Netherlands, 7500 KA
Contact: Wieger I de Bruin, MD    +31 53 4872088    w.debruin@mst.nl   
Principal Investigator: Wieger I de Bruin, MD         
Isala Clinics
Zwolle, Overijssel, Netherlands, 8025 AB
Contact: Piet L Jager, MD PhD    +31 38 424 7909    p.l.jager@isala.nl   
Principal Investigator: Piet L Jager, MD PhD         
Meander Medical Center
Amersfoort, Utrecht, Netherlands, 3818 ES
Contact: John MH de Klerk, MD PhD    +31338505050 ext 2876    jmh.de.klerk@meandermc.nl   
Principal Investigator: John MH de Klerk, MD PhD         
St. Antonius hospital
Nieuwegein, Utrecht, Netherlands, 3435 CM
Contact: Jules Lavalaye, MD PhD    +31 88 320 3000    j.lavalaye@antonius.net   
Principal Investigator: Jules Lavalaye, MD PhD         
Leiden University Medical Center
Leiden, Zuid-Holland, Netherlands, 2333ZA
Contact: Bernies van der Hiel, MD PhD    +31715263475    b.van_der_hiel@lumc.nl   
Contact: Daphne DD Rietbergen, MD    +31715263466    D.D.D.Rietbergen@lumc.nl   
Principal Investigator: Bernies van der Hiel, MD PhD         
University Medical Center Groningen
Groningen, Netherlands, 9700 RB
Contact: Adrienne H Brouwers, MD PhD    +31503611319    a.h.brouwers@ngmb.umcg.nl   
Principal Investigator: Adrienne H Brouwers, MD PhD         
University Medical Center Utrecht
Utrecht, Netherlands, 3584 CX
Contact: Bart de Keizer, MD PhD    +31 88 755 5555 ext 1794    b.dekeizer@umcutrecht.nl   
Principal Investigator: Bart de Keizer, MD PhD         
Sponsors and Collaborators
The Netherlands Cancer Institute
Amsterdam UMC, location VUmc
UMC Utrecht
Layout table for investigator information
Principal Investigator: Marcel PM Stokkel, MD PhD The Netherlands Cancer Institute
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: The Netherlands Cancer Institute
ClinicalTrials.gov Identifier: NCT01641679    
Other Study ID Numbers: NL37266.031.11
M11TRP ( Other Identifier: PTC NKI-AVL )
First Posted: July 17, 2012    Key Record Dates
Last Update Posted: June 17, 2014
Last Verified: June 2014
Keywords provided by The Netherlands Cancer Institute:
Recurrent differentiated thyroid cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms